Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
← catalyst calendarNCT06479954 · readout in 190 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-30 | actual | When the study began enrolling |
| Primary completion | 2027-02-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-25 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed and Refractory Multiple Myeloma (RRMM)
Primary outcomes
what the primary-completion date above is the date OFIncidence of CRS events in adverse drug reaction
measured up to 52 weeks
Incidence of ICANS events in adverse drug reaction
measured up to 52 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed